Finance
Company attributes much of Q2's income drop to decline in ABELCET sales
Published in Hepatitis Weekly, March 21st, 2005
The company reported adjusted net income of $1.3 million or $0.03 per diluted share for the second quarter of FY 2005, versus adjusted net income of $2.3 million or $0.05 per diluted share for the second quarter of FY 2004.
The decrease in adjusted net income versus the prior year was primarily due to a $3.7 million decline in ABELCET sales and a $1.5 million decline in royalties, which are predominately made up of royalties from sales of PEG-INTRON.
The company's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-03-21)
More Articles from Hepatitis Weekly
- Blood Safety
Patients accidentally infected with hepatitis C respond well to interferon - Chronic Hepatitis C
Preliminary liver biopsies predict HCV-related liver fibrosis progression - Drug Resistance
Adefovir dipivoxil tackles all patterns of lamivudine-resistant hepatitis B - Food Safety
High hydrostatic pressure inactivates hepatitis A infection in oysters - Liver Transplantation
Adult living donor liver grafts offer a viable option to transplant candidates - Allergy and Immunology
CXCR6 recruits CD8 cells to the liver in graft vs. host disease - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
